Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
Resmed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for May 2025, with a reduction of 1,750,140 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock held on the NYSE. Additionally, there was a decrease in the total number of securities over which CDIs have not been issued, due to transfers between CDIs quoted on ASX and new share issues on the NYSE related to stock options and employee plans, as well as share repurchases.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc is a company operating in the healthcare industry, primarily focusing on the development and manufacturing of equipment related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative products that aid in the treatment of sleep apnea and other chronic respiratory diseases, positioning itself as a leader in the global market for sleep and respiratory care.
Average Trading Volume: 1,317,793
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$55.21B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.